TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Activities of daily living (ADL) performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-month outcomes of depression and substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tensile bond strength (MTBS) in MPa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sense of wellbeing improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Moderate/heavy bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in overall functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Remission based on parent-reported ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-rated hyperactivity and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical duration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portal venous blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD17 total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on PT procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive strategies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Carotid arterial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beta-stiffness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sulcus Bleeding Index (SBI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of oral mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MADRS total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSFQ total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients shifting from normal to abnormal sexual function
Endpoint domain: Adverse events/effects
Primary endpoint: Survival at 6, 12, 18, and 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of falling
Endpoint domain: Adverse events/effects
Primary endpoint: Age-adjusted risk of respiratory exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median reading time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apgar scores <7 at 1min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total score of self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: five-year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: five-year locoregional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SCORAD scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KT-1000 test value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of proinflammatory cytokines (IL-6, TNF-α, MMP-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in IADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving ≥ 5% weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital incidence of major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-day incidence of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluid-based time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean fluid-based magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effective fluid-based time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of platelet adhesion and aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Type V CPS-specific immunoglobulin G (IgG) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: UCCR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collagen crosslink excretion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of oral 5-FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic clearance of oral 5-FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist flexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood loss volumes up to day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of HDRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fogging prevention during nasal endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact on daily life
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Mean thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to loss of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete absence of draining fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Dry Skin scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: proportion of adequate biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diameter of biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic yield per biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Blood Pressure (CBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Augmentation Index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sustained improvement in American College of Rheumatology responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swollen joint counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Health Assessment Questionnaire disability index scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma levels of TNF-alpha, IL-6, and IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sexual activity at 12 months after radiation treatment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FiO2 during transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional capacity assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in heartburn symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in acid regurgitation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in bloating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total deaths
Endpoint domain: Mortality/survival
Primary endpoint: cancers
Endpoint domain: Mortality/survival
Primary endpoint: combination of deaths and cancers
Endpoint domain: Mortality/survival
Primary endpoint: Awake duration during the night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria transmission prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: vertebral height loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Long-term disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tissue sodium content in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Reductions in aspartate aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Reductions in alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Reductions in gamma‐glutamyl transferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Increases in bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Veq cutoff for VT patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre- and postintervention difference in Veq
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with valproate serum levels above 50 microg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite 'hard' endpoint of cardiovascular death, nonfatal MI and stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HADS-A <8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS-D <8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CSF Aβ42 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Red blood cell damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activation of coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinolysis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of delayed nausea and/or vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR-15) score on POD 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Persistence of sites with PD >4 mm and BOP at 12 months post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of AUDIT for alcohol use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of DAST for drug use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative cognitive function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of post-operative cognitive dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Time for post-operative consciousness recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hematocrit increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sTfR increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2max increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory block success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Weight-for-Age Z-score (WAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight-for-Height Z-score (WHZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of successful stone extraction within 10 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of CD4 and CD4/CD8 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of acute exacerbation and hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Disposition of open-mindedness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical resolution of the baseline infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of bacterial eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy/fatigue improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Functional independence (modified Rankin Scale scores, 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: clinically driven target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning blood ketone level ≥0.6 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: days of work/school missed for asthma
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: use of short-acting bronchodilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day death/MI rate
Endpoint domain: Mortality/survival
Primary endpoint: One-year unadjusted mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of hospital and intensive care unit days
Endpoint domain: Resource use
Primary endpoint: Responsive rate to bronchodilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Log C5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of negative conversion of secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control time of malodor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control time of exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine albumin-to-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional Reach Test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment effect of ACE-inhibitor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of clients with mild psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with no movement side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of mild akathisia
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of acute radiation therapy side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Sputum interleukin‐8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal expiratory flow at 25% (MEF25%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: OLP severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal (GI) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Control of Chemotherapy-Induced Nausea and Vomiting (CINV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: High-density lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activity of erythrocyte SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Organ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: recovery times
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PASI 75 response rate
Endpoint domain: Physiological/clinical
Primary endpoint: Deterioration of liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of taps for treatment of refractory ascites
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hip extension moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ankle plantar flexion moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: knee extension moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative incidence of incisional hernia
Endpoint domain: Mortality/survival
Primary endpoint: Abdominal pain at 6 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Time to complete wound healing of surgical site infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incident rates of IFN‐α‐induced depression
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of IFN‐induced depression
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with cosmetic results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clearance of SBECD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Collagen-adenosine diphosphate closure times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual loss of kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal composite outcome (40% reduction in eGFR, ESKD, or renal-related death)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of ASN development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of NVG development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala response to fearful faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CT erosion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plain radiographic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxygenation (paO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary shunt (Qs/Qt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FHR abnormalities requiring cesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Operative delivery for poor progress in labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Deterioration of MVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of poor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of moderate recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: treadmill distance walked to onset of claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accelerometer-derived daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning